Significant association of MCP1 rs1024611 and CCR2 rs1799864 polymorphisms with colorectal cancer and liver metastases susceptibility and aggressiveness: A case-control study.

[1]  Y. Zhan,et al.  Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds? , 2021, Frontiers in Immunology.

[2]  F. Aires-da-Silva,et al.  Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy , 2021, International journal of molecular sciences.

[3]  Wei Yu,et al.  CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment , 2021, Frontiers in Oncology.

[4]  Fan Wu,et al.  Perspectives on Immunotherapy of Metastatic Colorectal Cancer , 2021, Frontiers in Oncology.

[5]  G. Barosi,et al.  Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis , 2021, Cancers.

[6]  V. Ravichandiran,et al.  MCP-1: Function, regulation, and involvement in disease , 2021, International Immunopharmacology.

[7]  Po-Chun Chen,et al.  Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma , 2020, Journal of Experimental & Clinical Cancer Research.

[8]  Q. Hao,et al.  CCL2/CCR2 signaling in cancer pathogenesis , 2020, Cell Communication and Signaling.

[9]  A. Hartmann,et al.  CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage , 2020, Cancers.

[10]  K. Midwood,et al.  More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis , 2019, Front. Immunol..

[11]  Xiaoping Zhou,et al.  Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer , 2019, Cancer science.

[12]  A. Kow.  Hepatic metastasis from colorectal cancer. , 2019, Journal of gastrointestinal oncology.

[13]  Xingang Lu,et al.  Histological tumor response assessment in colorectal liver metastases after neoadjuvant chemotherapy: impact of the variation in tumor regression grading and peritumoral lymphocytic infiltration , 2019, Journal of Cancer.

[14]  T. Oguri,et al.  Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients , 2019, BMC Cancer.

[15]  Tianmin Xu,et al.  Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview , 2019, Front. Oncol..

[16]  R. Adam,et al.  Multidisciplinary approach of liver metastases from colorectal cancer , 2019, Annals of gastroenterological surgery.

[17]  Y. Puckett,et al.  Literature Review of Current Management of Colorectal Liver Metastasis , 2019, Cureus.

[18]  Bo W. Han,et al.  Association of MCP‐1 promoter polymorphism with susceptibility to nasopharyngeal carcinoma , 2018, Journal of cellular biochemistry.

[19]  P. Proost,et al.  Chemokine-Induced Macrophage Polarization in Inflammatory Conditions , 2018, Front. Immunol..

[20]  Tiantian Zhao,et al.  CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. , 2018, Oncology letters.

[21]  Jianwei Zhou,et al.  CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer , 2018, International journal of biological sciences.

[22]  N. Bercovici,et al.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.

[23]  Xiuzhen Zhang,et al.  The rs1024611 in the CCL2 gene and risk of gynecological cancer in Asians: a meta-analysis , 2018, World Journal of Surgical Oncology.

[24]  T. Yoshimura.  The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? , 2018, Cellular & Molecular Immunology.

[25]  I. Majsterek,et al.  An association of the MCP-1 and CCR2 single nucleotide polymorphisms with colorectal cancer prevalence. , 2017, Polski przeglad chirurgiczny.

[26]  M. Hsairi,et al.  Colorectal Cancer Incidence Trend and Projections in Tunisia (1994 - 2024) , 2017, Asian Pacific journal of cancer prevention : APJCP.

[27]  T. Yoshimura.  The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. , 2017, Cytokine.

[28]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[29]  N. Kim,et al.  Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). , 2017, Oncology reports.

[30]  Gina Brown,et al.  Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales , 2016, World journal of gastroenterology.

[31]  M. Sokołowska-Wojdyło,et al.  –2518 A/G MCP-1 but not –403 G/A RANTES gene polymorphism is associated with enhanced risk of basal cell carcinoma , 2016, Postepy dermatologii i alergologii.

[32]  Xianglin Shi,et al.  Role of MCP‐1 in alcohol‐induced aggressiveness of colorectal cancer cells , 2016, Molecular carcinogenesis.

[33]  M. Watanabe,et al.  CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer , 2016, Clinical and Experimental Medicine.

[34]  Hong Yang,et al.  MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial–mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells , 2016, Cellular &Molecular Immunology.

[35]  S. Crovella,et al.  CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study , 2016, Memorias do Instituto Oswaldo Cruz.

[36]  R. Muschel,et al.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.

[37]  J. Weiss,et al.  Induction of Monocyte Chemoattractant Proteins in Macrophages via the Production of Granulocyte/Macrophage Colony-Stimulating Factor by Breast Cancer Cells , 2016, Front. Immunol..

[38]  T. Zeng,et al.  CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway , 2015, Oncotarget.

[39]  Stephanie A. Bien,et al.  Genetic architecture of colorectal cancer , 2015, Gut.

[40]  L. Yang,et al.  Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China. , 2015, Genetics and molecular research : GMR.

[41]  D. Grootendorst,et al.  CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. , 2014, Clinical colorectal cancer.

[42]  Shuai Zhang,et al.  Association between MCP-1 -2518A/G Polymorphism and Cancer Risk: Evidence from 19 Case-Control Studies , 2013, PloS one.

[43]  Jeongseon Kim,et al.  Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of cancer: a meta-analysis. , 2013, Cytokine.

[44]  Guangwei Liu,et al.  Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma , 2013, Tumor Biology.

[45]  S. Erdamar,et al.  Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? , 2013, Tumor Biology.

[46]  A. Tolcher,et al.  A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[47]  O. Sanli,et al.  The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. , 2012, Gene.

[48]  S. Mummidi,et al.  The rs1024611 Regulatory Region Polymorphism Is Associated with CCL2 Allelic Expression Imbalance , 2012, PloS one.

[49]  O. Sanli,et al.  Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. , 2012, DNA and cell biology.

[50]  Gary L Gilliland,et al.  Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888. , 2012, Molecular immunology.

[51]  Mu-Kuan Chen,et al.  CCR2-64I gene polymorphism increase susceptibility to oral cancer. , 2011, Oral oncology.

[52]  L. Hou,et al.  Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population , 2011, Scandinavian journal of gastroenterology.

[53]  M. Chou,et al.  Genetic polymorphism of CCR2‐64I increased the susceptibility of hepatocellular carcinoma , 2010, Journal of surgical oncology.

[54]  A. Williamson,et al.  CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women , 2010, BMC Cancer.

[55]  K. Pienta,et al.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.

[56]  T. Isbir,et al.  CCR2-64I is a risk factor for development of bladder cancer. , 2010, Genetics and molecular research : GMR.

[57]  D. Qian,et al.  CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity , 2010, The Prostate.

[58]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[59]  Matthew J. Craig,et al.  CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.

[60]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[61]  M. Miyazaki,et al.  Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. , 2009, International journal of oncology.

[62]  F. Garrido,et al.  Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer , 2008, BMC Cancer.

[63]  Hsiu‐Po Wang,et al.  RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women , 2008, Journal of Gastroenterology.

[64]  P. Magnusson,et al.  Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer , 2007, International journal of cancer.

[65]  Kai-Ping Chang,et al.  MCP-1 Promoter Polymorphism at −2518 Is Associated with Metastasis of Nasopharyngeal Carcinoma after Treatment , 2007, Clinical Cancer Research.

[66]  R. Catarino,et al.  The Influence of Chemokine Receptor CCR2 Genotypes in the Route to Cervical Carcinogenesis , 2007, Gynecologic and Obstetric Investigation.

[67]  W. Gong,et al.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. , 2007, Cancer letters.

[68]  Matthew J. Craig,et al.  CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases , 2007, Cancer and Metastasis Reviews.

[69]  R. Catarino,et al.  Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. , 2005, Gynecologic oncology.

[70]  A. La Torre,et al.  Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. , 2005, Clinical chemistry.

[71]  Yuetsu Tanaka,et al.  A CCR2-V64I polymorphism affects stability of CCR2A isoform , 2004, AIDS.

[72]  S. Sanders,et al.  Functional Differences Between Monocyte Chemotactic Protein-1 Receptor A and Monocyte Chemotactic Protein-1 Receptor B Expressed in a Jurkat T Cell , 2000, The Journal of Immunology.

[73]  B. Rovin,et al.  A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. , 1999, Biochemical and biophysical research communications.

[74]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[75]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[76]  Xin Wei,et al.  Functional polymorphisms in monocyte chemoattractant protein-1 are associated with increased susceptibility to ovarian cancer. , 2015, DNA and cell biology.

[77]  R. Mandal,et al.  Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer , 2014, Tumor Biology.

[78]  Li Li,et al.  Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer , 2014, Tumor Biology.

[79]  M. S. Khan,et al.  Association of Chemokine and Chemokine Receptor Gene Polymorphis (MCP1 A-2518G and CCR2-V64I) with Urinary Bladder Cancer: A Study in Kashmiri Population , 2013 .

[80]  J. Davis,et al.  Intestinal inflammatory cytokine response in relation to tumorigenesis in the Apc(Min/+) mouse. , 2012, Cytokine.

[81]  D. Heitjan,et al.  CCL2 blockade augments cancer immunotherapy. , 2010, Cancer research.